Point State Capital LP Puma Biotechnology, Inc. Transaction History

Point State Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $15.2 Million - $21.5 Million	-315,183 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $5.37 Million - $8.93 Million	89,951 Added 39.94%	315,183 $21.4 Million
Q4 2017 Feb 14, 2018	SELL	$93.85 - $132.45 $17.7 Million - $25 Million	-188,778 Reduced 45.6%	225,232 $22.3 Million
Q3 2017 Nov 14, 2017	SELL	$72.0 - $119.75 $13.8 Million - $22.9 Million	-191,350 Reduced 31.61%	414,010 $49.6 Million
Q2 2017 Aug 14, 2017	BUY	N/A	605,360	605,360 $52.9 Million

110

28.3M

27.9K

3.4K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.